SecBot SecBot
8-K ·Filed May 14, 2026

BFRIW

Biofrontera Inc.
MIXED
Impact 5/10
Horizonweeks Processed5mo ago SEC0001493152-26-022875
8-K Item 2.02: Earnings release
Actionable Insight ◆ Mixed

Revenue slightly missed consensus but cash burn improvement to near-zero is a positive signal. The sBCC PDUFA in September 2026 is the key catalyst. Monitor for any guidance updates on the earnings call.

DirectionMixed
Confidencehigh
Horizonweeks
Latest settled — T+20d
BFRIW ▲ 0.00% at T+20d
NEUTRAL call 0.00% · α vs SPY +0.86% · entry $0.0630 → $0.0630
Next anchor: T+60d due 3mo ago
Entry = T+0 close
May 14, 2026
via day close
T+1d
0.00%
call 0.00% · α +1.23%
$0.0630
settled 5mo ago
T+5d
0.00%
call 0.00% · α +0.72%
$0.0630
settled 5mo ago
T+20d
0.00%
call 0.00% · α +0.86%
$0.0630
settled 5mo ago
T+60d
Pending
due 3mo ago

Price Chart

Loading chart...

Executive Summary

Biofrontera Inc. reported Q1 2026 revenue of $10.1M, up ~17% YoY from $8.6M, but slightly below the $10.3M consensus. Net loss widened to $4.8M from $4.2M, though operating cash burn improved dramatically to just $70K from $4.1M a year ago. The company highlighted a PDUFA date for sBCC in September 2026 and near-zero cash consumption as key catalysts.

Key Financial Metrics

EPS
−$0.41
Revenue
$10.1M
est $10.3M · -2.1% · +17.4% YoY
Rating
in line
Gross Margin
80%

Key Facts

  • Q1 2026 revenue of $10.1M, up ~17% YoY from $8.6M, but below consensus of $10.3M
  • Net loss of $4.8M ($0.41/share) vs $4.2M ($0.47/share) in Q1 2025
  • Gross margin expanded to ~80% from ~62% YoY, driven by new earnout structure
  • Operating cash burn nearly eliminated at $70K used vs $4.1M in Q1 2025
  • Cash balance of $6.3M as of March 31, 2026
  • PDUFA target action date for sBCC is September 28, 2026
  • Regained Nasdaq minimum bid price compliance on May 6, 2026

Financial Impact

Revenue $10.1M vs $10.3M consensus (miss of ~2%); net loss $4.8M vs $4.2M prior year; operating cash flow improved to -$70K from -$4.1M

revenuenet lossoperating cash flowgross margin

Risk Factors

  • Revenue miss vs consensus could pressure the stock near-term
  • Still unprofitable with accumulated deficit of $127.9M
  • Dependence on Ameluz PDT platform and regulatory approval for sBCC
  • Warrant liability fair value changes create earnings volatility

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations

Investment Themes

Biotech & Drug Discovery

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001493152-26-022875
Document: form8-k.htm0001493152-26-022875
Document: 0001493152-26-022875-index-headers.html0001493152-26-022875
Document: 0001493152-26-022875-index.html0001493152-26-022875
Document: 0001493152-26-022875.txt0001493152-26-022875
8-K Data (Synthetic)0001493152-26-022875

US Market Status

Market Open — Closes in 5h 14m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published May 14, 2026